DNA Marker, Post BMT Engraftment, Blood CD19/56


     
Order Code:LAB1133Order Name:BMT Marker Post BMT CD29/56
Order Instructions:For bone marrow order LAB4907; for CD3 and CD33 sort, order LAB4608. If sorts for CD3, CD33, CD19 and CD56 are needed, order LAB4608 and LAB1133.
Synonyms:Bone Marrow Transplant DNA Marker; Bone Marrow Transplant Engraftment Evaluation; Post BMT Chimerism Study; Molecular
Methodology:Amplification of DNA by polymerase chain reaction followed by separation by capillary electrophoresis.
CPT Codes: 81268 x1, G0452 x1, 81267 x1
Test Includes:Samples ordered for this test will be sorted to CD19+(B cell) and 56+(NK cell) when appropriate. See Contraindications.
Turnaround Time:Performed Mon-Fri; results are reported within 3 days,


Collection Instructions

Specimen:Blood, isolated cells
Container:Yellow (ACD, Solution A) tube available from laboratory
Alternate Containers: Purple (EDTA)
Collection Instructions:
  • Peripheral Blood: Collect 10 mL (* ml minimum) in yellow ACD (Solution A) tube; alternate container: purple (EDTA) tube.
  • Isolated Cells: Deliver to the lab within 1 hour or freeze.

If sorts for CD3, CD33, CD19 and CD56 are needed, order LAB4608 and LAB1133. Two tubes MUST be collected. Minimum volume 14 mL.
Causes for Rejection:Frozen or clotted specimens, or incorrect anticoagulant.
Shared samples will not be accepted unless sent to Molecular first. Contamination will occur on automated hematology analyzers.
DNA extracted at non-CLIA certified (or equivalent) lab.
Contraindications:Specimens with WBC <1.0 x 109/L will not be isolated into CD19+ and CD56+ fractions. Samples greater than 48 hours old will not be separated.


Processing and Shipping

Specimen Processing:Store at room temperature.
Shipping Instructions:Ship at room temperature. Must arrive within 24 hours. Specimens received after 1400 Friday thru Sunday will not be processed until Monday.
Test Performed at or Referral Lab Molecular Diagnostics  (UMMC East)


Interpretive

Use:Allogeneic hematopoietic cell transplant (HCT) is a therapeutic option available for treatment of numerous malignancies and inherited genetic disorders. Monitoring engraftment following allogeneic HCT is necessary for early documentation of engraftment, detection and timely treatment of graft rejection or early relapse. The presence of lympho-hematopoietic cells of donor origin after allogeneic HCT is referred to as "chimerism". The kinetics of engraftment in different cell popuations has been found to be different among T cells, Natural Killer (NK) cells, granulocyutes and monocytes. Generally donor T cell chimerism has been found to lag behind donor myeloid chimerism. Early patterns of T and NK cell chimerism have predicted patients at increased risk of graft rejection and gract versus host disease. Hence lineage-specific chimerism (i.e. monitoring of engraftment in specific subsuts) may provide valuable clincial information in identifying patients at high risk for adverse clinical events.


Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
systemlabguide@fairview.org for TestID: 6916"